Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

This study has been completed.
Daiichi Sankyo Co., Ltd.
Information provided by (Responsible Party):
Taiho Pharmaceutical Co., Ltd. Identifier:
First received: January 30, 2006
Last updated: November 1, 2012
Last verified: November 2012